Sources last read
Trulicity dosage schedule
Trulicity starts at 0.75 mg once a week. Its maximum dose is 4.5 mg. The 0.75 mg dose can continue for blood sugar control. Further increases depend on response.
Source for this answer
Source: Read from the Trulicity label, revision 03/2026
Source: Read from the Trulicity label, revision 03/2026
Medically reviewed by Jennifer Montecillo, MD · non-practicing medical reviewerReviewed 2026-08-13every number here is sourced
Key dose facts
Key facts
- 0.75 mg once a week
- 0.75 mg can continue; increases depend on blood sugar control
- 4.5 mg once a week
- Shown step by step below
The Trulicity dosages, step by step
The label does not print a week-by-week table for Trulicity. It gives the first four weeks, then says each move up needs at least four weeks on the dose before it. So the timing column repeats the label’s own wording rather than turning it into week numbers.
| When | Weekly dose | Can you stay here? | What the label notes |
|---|---|---|---|
| Weeks 1 through 4 | 0.75 mg | Yes | Starting dosage; can continue for blood sugar control |
| After 4 weeks | 1.5 mg | Yes | The ceiling for patients aged 10 to 17 |
| After at least 4 weeks on 1.5 mg | 3 mg | Yes | Adults only, and only where blood sugar needs more help |
| After at least 4 weeks on 3 mg | 4.5 mg | Yes | Maximum for adults |
Which dose do you end up on?
The Trulicity label names no set of doses to settle on. It starts at 0.75 mg, allows a move to 1.5 mg after four weeks, and then rises in 1.5 mg steps where blood sugar needs more help. What marks it out is the bottom rung. Ozempic says its 0.25 mg start is not a blood sugar dose and Victoza says the same of its 0.6 mg. The Trulicity label says no such thing about 0.75 mg.
| Who the label covers | Dose to settle on | Approved |
|---|---|---|
| Adults with type 2 diabetes, alongside diet and exercise, to improve blood sugar control | 0.75 mg once weekly, raised in steps to 4.5 mg where blood sugar needs more help | 2014-09-18BLA 125469 |
| Children and teenagers aged 10 years and older with type 2 diabetes, alongside diet and exercise | 0.75 mg once weekly, raised once to 1.5 mg where blood sugar needs more help | 2022-11-17BLA 125469/S-051 |
| Adults with type 2 diabetes who have either established cardiovascular disease or several cardiovascular risk factors, to lower the risk of cardiovascular death, non-fatal heart attack or non-fatal stroke | The same step pattern the label sets for blood sugar | 2020-02-21BLA 125469/S-033 |
4.5 mg once weekly is the maximum for adults. For pediatric patients aged 10 years and older, the maximum is 1.5 mg once weekly.
8Label details
Who does the label cover, and who does it not?
Patients aged 10 and older with type 2 diabetes are covered. They start where adults start, at 0.75 mg, and the label allows one step up to 1.5 mg. That is the end of the ladder for them. Nothing is established below age 10.
The Trulicity label covers type 2 diabetes and nothing else. It sets no dose for weight, and Lilly never gave dulaglutide a second brand for weight the way it gave tirzepatide one. Drugs@FDA lists dulaglutide under one application and no others, and that application is a biologics license — which is a route with no generic at the end of it.
What if a week gets missed?
The label ties the answer to the gap ahead rather than the gap behind. If the next scheduled dose is at least 3 days off, which is 72 hours, a missed dose can still go in. Under 3 days, the label says to skip it and take the next one on the usual day.
The label allows the weekly day to move as long as the last dose went in 3 or more days before the new day.
What does it come in?
The device matters for dosing, because some of these hold one dose and some hold four.
| Device | Strengths | Doses inside |
|---|---|---|
| Single-dose pen | 0.75, 1.5, 3 and 4.5 mg per 0.5 mL | 1 dose, in a carton of 4 |
How long does it take to reach the 4.5 mg dose?
The label does not promise one date. It sets the timing for each step in the schedule below.
Trulicity starts at 0.75 mg and has a 4.5 mg ceiling. Read the published timing beside each row rather than adding the waits into one calendar estimate.
Nothing in the label says a person has to keep climbing. The maintenance choices are listed separately below.
Whether to move up, stay put or stop is a decision for whoever wrote the prescription.
Can you stay on a low dose of Trulicity?
The label allows 0.75 mg for ongoing blood sugar control. Higher doses depend on whether more control is needed.
There is no fixed list of maintenance doses. That does not mean everyone has to leave the starting dose.
The label allows an increase only when more blood sugar control is needed, after at least four weeks on the current dose.
The maximum is 4.5 mg for adults. The dose that suits one person is a decision for their prescriber.
How does the Trulicity schedule compare with other GLP-1 brands?
Trulicity tops out at 4.5 mg once a week. Compare starting and ongoing doses for the 9 brands below.
The table below compares the highest labeled doses, starting doses and ongoing dose choices. Each row comes from that product’s label.
Milligrams do not carry across molecules. 4.5 mg of dulaglutide is not comparable to 4.5 mg of anything else. The last column says so on every row where the drug substance differs.
Brands can share a drug but differ in form, approved use or dose schedule. A matching milligram amount does not make products interchangeable.
| Brand | Drug | Starts at | Tops out at | Doses to stay on | Against Trulicity |
|---|---|---|---|---|---|
| Foundayo | Orforglipron | 0.8 mg daily | 17.2 mg | 5.5 mg can continue; further increases depend on response and tolerability | Different drug — milligrams do not compare |
| Zepbound | Tirzepatide | 2.5 mg weekly | 15 mg | 5, 10 and 15 mg | Different drug — milligrams do not compare |
| Mounjaro | Tirzepatide | 2.5 mg weekly | 15 mg | 2.5 mg can continue; increases depend on blood sugar control | Different drug — milligrams do not compare |
| Rybelsus | Semaglutide | 3 mg daily | 14 mg | 7 and 14 mg | Different drug — milligrams do not compare |
| Wegovy | Semaglutide | 0.25 mg weekly | 7.2 mg | 1.7, 2.4 and 7.2 mg | Different drug — milligrams do not compare |
| Trulicity | Dulaglutide | 0.75 mg weekly | 4.5 mg | 0.75 mg can continue; increases depend on blood sugar control | This page |
| Saxenda | Liraglutide | 0.6 mg daily | 3 mg | 2.4 and 3 mg | Different drug — milligrams do not compare |
| Ozempic | Semaglutide | 0.25 mg weekly | 2 mg | 0.5, 1 and 2 mg | Different drug — milligrams do not compare |
| Victoza | Liraglutide | 0.6 mg daily | 1.8 mg | 1.2 and 1.8 mg | Different drug — milligrams do not compare |
Do the side effects change as the dose goes up?
The Trulicity label includes side effects and warnings. This dosage guide does not include a trial-rate table.
A trial group’s assigned dose and each dose increase are different things. The table counts reports over the study, including time spent increasing doses.
These group results cannot tell someone whether a dose change caused their symptoms. Read each result with its trial group and study period.
The source label linked below contains the trial results and warnings. The schedule here gives the label’s timing for dose changes.
Where to read next
1 pages sit next to this one, and each answers something this page deliberately does not.
- What Trulicity costs reads the price off the manufacturer’s own terms rather than the label, including who those terms shut out.
- Trulicity (dulaglutide) injection — FDA-approved Prescribing Information (DailyMed)retrieved 2026-08-13FDA label
- Trulicity (dulaglutide) Prescribing Information, revised 03/2026 — Drugs@FDA BLA 125469/S-065retrieved 2026-08-13FDA label
- FDA licensing letter, BLA 125469 — Trulicity (dulaglutide), glycemic control in adults with type 2 diabetesretrieved 2026-08-13FDA label
- FDA supplement approval letter, BLA 125469/S-051 — expansion of the Trulicity glycemic-control indication to pediatric patients 10 years of age and olderretrieved 2026-08-13FDA label
- FDA supplement approval letter, BLA 125469/S-033 — Trulicity indication for reducing major adverse cardiovascular events in type 2 diabetes (REWIND)retrieved 2026-08-13FDA label
- Drugs@FDA via openFDA — every application containing dulaglutide, which is BLA 125469 and nothing elseretrieved 2026-08-13FDA label